-
'Dreams disappear' as Gaza students await evacuation to Italy
-
Golden relay double for Britain at Europeans as Marchand takes silver
-
Third European gold for Schilder in women's shot put
-
Barcelona's Araujo heads to Liverpool on loan
-
Golden relay double for Britain at Europeans as Marchand settles for silver
-
Tupac Shakur murder trial begins 30 years after rapper's death
-
US had hottest month on record in July
-
Russia bars only anti-war party from elections
-
Colombia quake leaves 69 dead, with more trapped under rubble
-
Boeing to divest tech ventures for stake in air-taxi startup
-
Bookmap Announces Partnership with Plus500 to Expand Futures Trading Access
-
Major quake rocks Colombia and neighbors, 18 confirmed dead
-
Barcelona turn down PSG offer for Torres
-
Brazil aircraft maker Embraer raises outlook after record revenue
-
Buildings collapse as major quake rocks Colombia and neighbors
-
Drought forces water restrictions across nearly 70 percent of France
-
Meta releases new AI model as Zuckerberg lays out vision
-
Europe wary as gas stocks languish at lows while winter looms
-
OFunded Enters the Prop Trading Market With Broker-Backed Infrastructure From OFinancial Markets
-
Freedom Holding Corp. Reports 40% Increase in Quarterly Revenue to $732.5 Million
-
What next for beleaguered FIFA president Infantino?
-
Stocks mostly flat with focus on US inflation
-
Greece contains new wind-driven fire near Athens
-
UK radio broke rules in announcing king's death: watchdog
-
Massive shake-up of Hungary media after Orban's exit
-
Europe braces for another summer heatwave
-
Days of heavy rain leave at least 16 dead in Philippines
-
Tentoglou keep bid for fourth Euro title on course, Nowicki misses out
-
Bezos consortium nears deal to buy Liverpool stake: report
-
MEXC Sponsors Yohani's Colombo Concert, Bridging Sri Lankan Culture and Global Digital Finance
-
Stocks mostly rise with focus on US inflation
-
Parts of Germany's Rhine could become unnavigable, group warns
-
Days of heavy rain leave at least 13 dead in Philippines
-
Base Markets Appoints Nazim Moussaoui as Head of Premium Clients and Partnerships
-
Ex-Thai MP shoots dead local official over money row
-
US, South Korea to drill for new threats from North
-
July was Spain's hottest month on record: weather agency
-
SCANDIC TRADE Ultimate 2.6 är färdigutvecklat – SNC SCANDIC ECO-Systemet är nu komplett
-
SCANDIC TRADE Ultimate 2.6 je hotový – systém SNC SCANDIC ECO je kompletní
-
SCANDIC TRADE Ultimate 2.6 jest gotowy – system SNC SCANDIC ECO jest kompletny
-
تم الانتهاء من تطوير SCANDIC TRADE Ultimate 2.6 – وبذلك أصبح نظام SNC SCANDIC ECO متكاملاً
-
SCANDIC TRADE Ultimate 2.6が完成――SNC SCANDIC ECOシステムが完成しました
-
स्कैंडिक ट्रेड अल्टीमेट 2.6 अब पूरा हो गया है – SNC स्कैंडिक इको-सिस्टम अब पूरी तरह से चालू है।
-
Record July heat in regions home to 900 mn people: AFP analysis
-
Embattled Infantino target of letter from three confederations
-
SCANDIC TRADE Ultimate 2.6이 완성되었습니다 – SNC SCANDIC ECO-시스템이 완성되었습니다
-
SCANDIC TRADE Ultimate 2.6 已正式推出——SNC SCANDIC ECO 系統現已完整建置
-
SCANDIC TRADE Ultimate 2.6 завершено — екосистема SNC SCANDIC стала повноцінною
-
SCANDIC TRADE Ultimate 2.6 завершена — экосистема SNC SCANDIC стала полноценной
-
SCANDIC TRADE Ultimate 2.6 is now complete – the SNC SCANDIC ECO-System is now fully operational
Moderna sues Pfizer, BioNTech for Covid-19 vaccine patent infringement
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"This groundbreaking technology was critical to the development of Moderna's own mRNA Covid-19 vaccine, Spikevax. Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna added.
US-based Pfizer said it has not received the lawsuit and declined to speak further, while Germany's BioNTech did not immediately reply to a request for comment.
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are both safe and effective.
The lawsuits -- to be filed in filed Friday both in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on coronaviruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
G.Schulte--BTB